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Plasma Myeloperoxidase Predicts Incident Cardiovascular
Risks in Stable Patients Undergoing Medical Management
for Coronary Artery Disease
W.H. Wilson Tang,1* Yuping Wu,2 Stephen J. Nicholls,1 and Stanley L. Hazen1
BACKGROUND: Myeloperoxidase (MPO) concentra-
tions predict adverse clinical outcomes in the setting of
acute coronary syndromes and heart failure, but the
prognostic role of MPO in stable patients with known
atherosclerotic burden is unclear.
METHODS: We examined plasma MPO concentrations
and their relationship with prevalent significant coro-
nary artery disease (defined as 50% stenosis in any
coronary vessel) and incidentmajor adverse cardiovas-
cular events (MACEs), including death,myocardial in-
farction, and stroke, in a 3-year prospective follow-up
study of 1895 patients undergoing elective coronary
angiography.
RESULTS: The median plasma MPO concentration was
101 pmol/L (interquartile range 68–187 pmol/L). Pa-
tients with plasma MPO concentrations322 pmol/L
(14.6%of population) had increased risk of developing
future MACEs [hazard ratio (HR) 1.78, 95% CI 1.33–
2.37, P 0.001], and MPO as a single variable predic-
tor of MACE showed an area under the ROC curve of
0.67. After adjusting for traditional cardiac risk factors,
creatinine clearance, B-type natriuretic peptide, and
high-sensitivity C-reactive protein (hsCRP), increased
MPO concentrations remained significantly associated
with incident MACEs over the ensuing 3-year period
(HR 1.71; 95% CI 1.27–2.30, P  0.001). In patients
with increased hsCRP, MPO322 pmol/L was associ-
ated with lower event rates than observed with MPO
322 pmol/L.
CONCLUSIONS: PlasmaMPO concentrations provide in-
dependent prognostic value for the prediction of long-
term incident MACEs in a stable, medically managed
patient population with coronary artery disease. In in-
dividuals with increased hsCRP concentrations, we ob-
served lower risk of incident MACEs when concomi-
tant MPO concentrations were low vs when MPO
concentrations were high.
© 2010 American Association for Clinical Chemistry
Although surgical or percutaneous revascularization
remains one of the useful tools in the management of
atherosclerotic coronary artery disease (CAD),3 the
majority of patients with recognized atherosclerotic
burden do not fulfill indications for imminent revas-
cularization. It is in this context that aggressive risk
factor modification, particularly when targeting high-
risk individuals, continues to serve a primary role in
preventing adverse consequences. The Clinical Out-
comes Utilizing Revascularization and Aggressive
Drug Evaluation (COURAGE) trial recently showed
comparable cardiovascular outcomes among stable
subjects with significant coronary atherosclerosis ran-
domized to treatment with either aggressive preventive
medical intervention or percutaneous coronary inter-
vention plus aggressive preventive medical interven-
tion (1 ). The ability to identify individuals at increased
risk for major adverse cardiac events among subjects
with existing atherosclerotic heart disease is of consid-
erable interest, so that new interventions and ap-
proaches might be developed for treatment of this
high-risk group. Indeed, early administration of statin
therapy in patients with evidence of systemic inflam-
mation [as indicated by increased high-sensitivity
C-reactive protein (hsCRP)] may have contributed to
improved cardiovascular outcomes (2 ).
Myeloperoxidase (MPO) is a leukocyte-derived
enzyme that has been shown to have multiple mecha-
nistic links with vulnerable plaque development (3 ).
Enriched within culprit lesions of subjects who experi-
ence sudden cardiac death (4 ),MPOhas been linked to
activation of protease cascades and both proapoptotic
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and prothrombotic pathways that are believed to be
involved in plaque fissuring (5, 6 ), development of su-
perficial erosions (4 ), and intracoronary thrombus
generation during sudden cardiac death (3 ). MPO has
also been shown to directly promote catalytic con-
sumption of nitric oxide, leading to development of
endothelial dysfunction (7, 8 ). SystemicMPO concen-
trations have been shown to provide prognostic value
in the setting of chest pain and acute coronary syn-
dromes (9, 10). On the other side of the spectrum, sys-
temic MPO concentrations independently predict risk
for development of incident cardiovascular disease and
death in apparently healthy middle-aged subjects in
epidemiological studies (11). Recently, it was reported
that in the setting of a high coronary artery calcium
score assessed by electron-beam computed tomogra-
phy in asymptomatic patients, concomitant increases
in MPO were associated with a substantial increase in
cardiovascular risk (12). Herein, we examine the po-
tential for plasmaMPO concentrations to identify who
may be at heightened long-term risk among a large
stable (nonacute) cohort of patients with angiographi-
cally documented coronary artery stenosis in the set-
ting of aggressive medical therapy for their coronary
artery disease.
Methods
STUDY POPULATION
The Cleveland Clinic GenBank study was a large,
single-center, contemporary, prospective cohort study
from 2001 to 2006 that established a well-characterized
clinical repository with clinical and longitudinal out-
comes data from consenting individuals undergoing
elective diagnostic coronary angiography (either car-
diac catheterization or coronary computed tomogra-
phy angiography). All GenBank participants gave writ-
ten informed consent, and the Institutional Review
Board of the Cleveland Clinic approved the study pro-
tocol. For this analysis, we examined 2460 consecutive
individuals without evidence of myocardial infarction
(cardiac troponin I 0.03 g/L) but with evidence of
significant atherosclerotic burden (50% stenosis at
any coronary artery), with blood samples collected for
biomarker analysis. Blood was collected before any
heparin administration.We excluded 565 subjects who
received percutaneous or surgical revascularization
within 30 days before or after cardiac catheterization to
ensure a patient cohort destined to receive medical
management of their coronary artery disease. Data
were recorded for standard cardiac risk factors includ-
ing age, sex, history of diabetes mellitus, cigarette
smoking, systolic blood pressure, and fasting lipids. Be-
cause the majority of participants had relatively pre-
served renal function, an estimate of creatinine clear-
ance (CrCl) was calculated using the Cockcroft–Gault
equation.
ENDPOINTS
Major adverse cardiovascular event (MACE) was de-
fined as death, nonfatal myocardial infarction, or non-
fatal cerebrovascular accident after enrollment. End-
points were collected by in-person prospective
follow-up including letter solicitation and reply cards,
chart review, and direct contact by study staff. We as-
certained adjudicated outcomes over the ensuing 3
years for all participants after enrollment.
PLASMA MPO ASSAY
Venous blood samples were collected in EDTA tubes
and immediately processed and frozen at80 °F until
analysis. Plasmamyeloperoxidase concentrations were
measured by use of the Abbott Architect platform (Ab-
bott Laboratories), a chemiluminescent automated
immunoassay using MPO-specific monoclonal anti-
bodies in a 2-step sandwich format. The assay has a
dynamic range of 0–10 000 pmol/L, with a limit of de-
tection 20.0 pmol/L and a functional sensitivity of
50.0 pmol/L (total CV 20%) (13). B-type natriuretic
peptide (BNP), hsCRP, serum creatinine, fasting blood
glucose, and fasting lipid profiles were also measured
simultaneously on the same platform.
STATISTICAL ANALYSIS
We used Student t-test or Wilcoxon rank-sum test for
continuous variables and 2 test for categorical vari-
ables to examine the difference between the groups;
Cochran–Armitage test for trend analyses across quar-
tiles; and ROC curve analyses and 5-fold cross-
validation to determine the optimal plasma MPO cut-
off. For a given cutoff, we used a logistic regression
model to estimate the risk of MACE. The 5-fold cross-
validation divides the data into 5 approximately
equally sized portions. A logistic regression model is
trained on 4 parts of the data and then estimates the
risk of MACE in the fifth part. This is repeated for each
of the 5 parts. We calculated the area under the curve
(AUC)with the estimated risk. This processwas carried
out for a grid of MPO cutoff values, ranging from 250
to 650 with an increment of 1. The optimal cutoff was
chosen to maximize AUC values. Kaplan–Meier anal-
ysis with Cox proportional hazards regressionwas used
for time-to-event analysis to determine hazard ratios
(HRs) and 95% confidence intervals (95% CIs) for
MACEs. Adjustments were made for individual tradi-
tional cardiac risk factors including age, sex, choles-
terol concentrations, systolic blood pressure, smoking
history, and family history of premature coronary ar-
tery disease, and CrCl, as well as standard cardiac bi-
omarkers such as BNP and hsCRP to predict incident
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3-year MACE risks. We evaluated the improvement in
model performance introduced by the inclusion of
MPO using net reclassification improvement (NRI)
and integrated discrimination improvement (IDI) as
described by Pencina et al. (14). P values compare
models with and without MPO. Both models were ad-
justed for traditional risk factors including age, sex,
smoking, HDL cholesterol, LDL cholesterol, systolic
blood pressure, and diabetesmellitus. Cutoff values for
NRI estimation used a ratio of 6:3:1 for low-,medium-,
and high-risk categories owing to the nonparametric
distribution. We estimated 3-year predicted probabil-
ities of a MACE event from random survival forests
methodology. All analyses were performed using R
2.8.0. A P value 0.05 was considered statistically
significant.
Results
SUBJECT CHARACTERISTICS
In our study cohort of 1895 subjects, the mean (SD)
and median plasma MPO concentrations were 199
(277) pmol/L and 101 pmol/L (interquartile range 68–
187 pmol/L), respectively. The baseline characteristics
of the study population are given in Table 1. The opti-
mal MPO cutoff value 322 pmol/L was determined
by ROC as described. Interestingly, patients with in-
creased plasmaMPOconcentrations (322 pmol/L, or
14.6% of study cohort) were more likely to have a his-
tory of myocardial infarction, a lower systolic blood
pressure, and lower concentrations of fasting triglycer-
ide and estimated CrCl than those with lower MPO
concentrations.
PLASMA MPO AND MACE
At 3 years of follow-up, a total of 279 first-time events
(including 184 deaths, 87 myocardial infarctions, 22
strokes, with some having more than 1 event) were
observed. The AUC for plasma MPO was 67%, and
increasing quartiles of MPO concentrations were asso-
ciated with higher rates of 3-year MACEs (P  0.01)
(Fig. 1). At optimal cutoff of 322 pmol/L, MPO was
predictive of higher 3-year MACEs (HR 1.78; 95% CI
1.33–2.37, P  0.001) (Fig. 2). After adjusting for tra-
ditional risk factors (including Framingham risk fac-
tors), CrCl, BNP, and hsCRP, plasma MPO 322
pmol/L remained independently predictive of 3-year
MACEs (HR 1.71; 95% CI 1.27–2.30, P  0.001).
Plasma MPO still provided incremental value in pre-
dicting 3-year MACEs when analyzed as continuous
variable with log-transformation (HR 1.26, 95% CI
1.11–1.43, P  0.001). Further, after adjustments for
traditional risk factors including Framingham risk fac-
tors and CrCl, BNP, and hsCRP, MPO remained an
independent predictor of 3-year all-cause mortality
(HR 1.71, 95% CI 1.26–2.31) and 3-year incident risk
of nonfatal MI (HR 1.85, 95% CI 1.13–3.05) (Table 2).
Moreover, addition of MPO to traditional risk factors
Table 1. Baseline characteristics.a
MPO <322 pmol/L MPO >322 pmol/L P value
n 1618 277
Demographics and cardiovascular risk factors
Age, years 64 (11) 63 (11) 0.329
Male, % 73 68 0.098
Diabetes mellitus, % 33 29 0.220
Hypertension, % 76 71 0.127
History of myocardial infarction, % 47 56 0.016
Systolic blood pressure, mmHg 133 (120–149) 130 (115–144) 0.012
Smoker (former or current), % 0.70 0.66 0.177
Laboratory data
BNP, ng/L 89 (39–205) 112 (42–245) 0.092
hsCRP, mg/L 2.0 (0.9–4.4) 2.2 (1.0–5.4) 0.052
LDL cholesterol, mmol/L 2.4 (1.9–2.9) 2.4 (1.8–2.8) 0.135
HDL cholesterol, mmol/L 0.8 (0.7–1.0) 0.8 (0.7–1.0) 0.088
Triglycerides, mmol/L 1.4 (1.0–1.9) 1.3 (0.9–1.9) 0.021
CrCl, mL  min1  (1.73 m2)1 76 (101–127) 74 (94–122) 0.027
a Data are mean (SD) or median (interquartile range).
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resulted in significant integrated discrimination im-
provement (IDI 10%,P 0.001) and significant event-
specific net reclassification (NRI 6%, P 0.022).
RELATIONSHIP BETWEEN MPO, hsCRP, AND
CARDIOVASCULAR RISK
There was weak correlation between plasma MPO and
hsCRP concentrations (Spearman r  0.186, P 
0.0001). Within the cohort of subjects with hsCRP2
mg/L, 14% of subjects had MPO concentrations322
pmol/L, and these patients demonstrated a higher risk
of adverse cardiac events in the ensuing 3 years than
those without increased plasma MPO concentrations
(Fig. 2). Equivalent risk for MACEs was observed
among those with high hsCRP 2 mg/L but low
plasmaMPO (322 pmol/L), vs those with highMPO
but low hsCRP—both representing the intermediate-
risk category with a single positive biomarker (Fig. 3).
Discussion
Previous studies have identified the prognostic role of
MPO following acute myocardial infarction (10),
acute heart failure (15), and chronic stable heart failure
(16) and in apparently healthy middle aged (11) or
elderly (17) subjects. Our study extends the ability of
MPO concentrations in risk prediction for vulnerable
plaque to the setting of stable patients undergoing elec-
tive coronary angiography for signs and symptoms
suggestive of coronary artery disease. The key finding
from this large, well-characterized cohort of stable pa-
tients undermedically managed coronary evaluation is
that higher plasma MPO concentrations portend
poorer long-term prognoses after adjusting for stan-
dard risk factors, cardiac-specific biomarkers, and al-
ternative markers of inflammation in the presence of
atherosclerotic burden. The results confirmed prior re-
ports of independent predictive value for long-term
cardiovascular mortality risk in coronary angiography
patients (18) and extend the results to observed in-
creased risks for 3-year incident nonfatal myocardial
infarction, stroke, or death. These results thus indicate
that MPO concentrations seem to provide prognostic
value in medically managed stable patients with CAD.
Further, when including those with revascularization
within 30 days (total n 2460), the prognostic value of
MPO remained statistically significant (unadjustedHR
1.71, 95% CI 1.32–2.22, P  0.001; adjusted HR 1.65,
95% CI 1.26–2.17, P 0.001). Further support of the
concept that MPOmay play a pathophysiologic role in
promoting vulnerable plaque across the spectrum of
atherosclerotic coronary artery disease may be seen by
the findings that in the setting of increased hsCRP, a
low MPO concentration may provide reassurance of
lower cardiovascular risk profile.
Participation of systemic inflammatory processes
in the development of adverse cardiovascular events
has been popularized with extensive literature on leu-
kocyte counts and hsCRP concentrations, although a
wide range of different inflammatory participants may
be involved (19). Although the majority of clinical
studies related to the prognostic role of MPO have fo-
cused on the acute ischemic setting (7, 9, 10, 20), re-
cent data suggest that higher concentrations ofMPO in
apparently healthy individuals may predict future de-
velopment of coronary events, particularly in those
with evidence of subclinical atherosclerotic plaque
(11, 12). The MPO concentrations measured in this
patient cohort appeared lower than those previously
reported, in part because of the different assays being
used (13) and also because of the relatively stable,med-
icallymanaged patient population being studied (some
of which may not even have raised MPO concentra-
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tions, as previously described (21)). A strength of this
analysis is the direct evidence of atherosclerotic burden
as demonstrated by presence of significantly ob-
structed coronary arteries determined by coronary an-
giography, which is the clinical gold standard, rather
than relying on clinical history or events as determina-
tion of underlying plaque vulnerability. This may also
explain why a previous smaller study did not demon-
strate significant differences in prognosis between high
and low MPO concentrations in patients with stable
angina where atherosclerotic burden was not known
(22).We also included only thosewith significant CAD
and followed a standardMACE outcome at 3 years in a
patient population treated with contemporary medical
therapy, which differs from a smaller published study
including both CAD and non-CAD subjects with car-
diac mortality at 13-year follow-up as endpoint (18).
Our findings provide further insight into the use of
biomarkers to better predict the natural history of cor-
onary atherosclerosis, particularly in the context of an
ongoing debate regarding the pros and cons of invasive
vs conservative medical approach to the treatment of
coronary artery disease. In the COURAGE trial, there
was no significant reduction in the risk of death, myo-
cardial infarction, or othermajor cardiovascular events
when percutaneous coronary intervention was added
to optimal medical therapy (1 ). Our patient cohort
has comparable event rates (14.7% at 3 years) al-
though with a slightly lower degree of coronary ste-
nosis (at least 70% stenosis in any coronary artery in
COURAGE). Our findings further demonstrated that
by assessing both MPO and hsCRP at their respective
cutoff values, about 57% of subjects with higher risk of
developing future MACEs can be identified. In con-
trast, we observed that among those with increased
hsCRP (2 mg/L), a low concentration of MPO is as-
sociated with reduced risk for MACEs. Whether this
population can benefit frommore aggressive risk factor
modification or pharmacologic therapy (such as high-
dose statins above and beyond current guideline rec-
ommendation targets, as implicated in a recent trial
targeting increased hsCRP to initiate statin therapy
(2 )) will require further investigations.
Another interesting finding of the present study is
the lack of a strong association between MPO and
hsCRP, an observation that has also been reported in
several previous studies with alternative populations
(9, 21, 23, 24). These findings suggest that MPO con-
centrations help to differentiate a leukocyte-based
pathophysiologic contribution to cardiovascular dis-
ease, from a generalized systemic inflammatory pro-
cess as monitored only with positive acute-phase
proteins such as C-reactive protein. Indeed, being en-
riched in vulnerable plaques (25), MPO serves as an
enzymatic source of eicosanoids and bioactive oxidized
lipids that can generate atherogenic forms of lipopro-
teins (26). Mechanistic studies have also indicated that
MPO catalyzes the formation of several reactive oxi-
dant species and impacts regional nitric oxide concen-
trations (7, 8 ). Interestingly, MPO concentrations
demonstrate strong correlations with the degree of en-
dothelial dysfunction, independent of hsCRP values
and coronary artery disease status (23), and this pro-
cessmay also have contributed to increased vulnerabil-
ity of atherosclerotic plaque by increasing athero-
thrombotic risk, as well as ischemic burden. MPO has
been shown to enhanced tissue factor pathway activity
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Table 2. Prognostic value of plasma MPO above a cutoff of 322 pmol/L in the prediction of MACEs.
3-Year MACE 3-Year death
3-Year nonfatal
myocardial infarction 3-Year nonfatal stroke
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Unadjusted 1.78 (1.33–2.37) 0.001 1.78 (1.25–2.53) 0.001 1.88 (1.14–3.09) 0.013 1.38 (0.47–4.07) 0.557
Adjusteda 1.71 (1.27–2.30) 0.001 1.71 (1.26–2.31) 0.001 1.85 (1.13–3.05) 0.015 1.58 (0.51–4.89) 0.426
a Adjusted for age, sex, LDL and HDL cholesterol, systolic blood pressure, former or current cigarette smoking, diabetes mellitus, history of myocardial infarction,
CrCl, BNP, and hsCRP.
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levels in coronary endothelium (27), and MPO-
generated oxidized lipids have been shown tomodulate
platelet hyperresponsiveness in the setting of dyslipide-
mia (28). These observations may help to further ex-
plain why MPO concentrations provide independent
prognostic value in predicting future MACE in a car-
diac troponin–negative cohort even when adjusted for
traditional cardiac risk factors and novel cardiac bi-
omarkers such as hsCRP and BNP concentrations.
There are several limitations of the study. The lack
of direct visualization of plaque composition or a uni-
versal definition of vulnerable plaque precludes recog-
nition of any association between systemic MPO con-
centrations and plaque characteristics. Whereas the
decision not to proceed with revascularization in the
presence of significantly obstructive atherosclerotic
coronary artery disease was determined by the treating
physicians who were blinded to MPO plasma concen-
trations, this factormay still have allowed the introduc-
tion of a selection bias in the subject cohort from the
presence of potential confounding factors that may
have affected such clinical decisions. The small event
rates of cerebrovascular accidents in our cohort limited
our ability to determine the prognostic value of MPO
in predicting future occurrences of such events. Fur-
thermore, our results were based on a cut point opti-
mized in this dataset, and hence may overestimate the
strength of the risk relationship. With different studies
using different assays with different cutoff values for
different populations, there is a need to identify clini-
cally useful cut points through a consensus of results
based on FDA-cleared assay results. Although the data
on interventions that can directly influence outcomes
in patients with high MPO concentrations remain
sparse, there have been mechanistic studies identifying
the potential role of therapy with high-dose statins
such as rosuvastatin that can reduce MPO concentra-
tions in humans (29). Hence, in parallel with results
from trials targeting high hsCRP (2 ), increased MPO
concentrations may warrant more intensive treatment
goals for modifiable risk reduction. Of interest, several
inhibitors of MPO are currently commencing early-
phase clinical investigations, and therefore a targeted
reduction of MPO activity may become feasible in the
future.
In conclusion, plasma MPO concentrations pro-
vide independent prognostic value for the prediction of
long-term incident MACEs in a stable, medically man-
aged patient population with coronary artery disease.
In individuals with increased hsCRP concentrations
and concomitantly low MPO concentrations, we ob-
served lower risk of incident MACEs than that for in-
dividuals in whom both marker values were high.
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